Iranian Researcher Offers New Formulation for Risperidone
Preparation of formulation and evaluation of injectable hydrogel system containing triblock PLGA-PEG-PLGA made by carbon dioxide Supercritical fluid extraction and PLGA containing risperidone" was the title of a research project conducted by Farzin Hadizadeh, a professor at Mashhad University of Medical Sciences, which he completed with the support of the Iran National Science Foundation (INSF), a report by the Iranian Vice Presidency for Science and Technology and Knowledge-Based Economy.
“Schizophrenia is one of the severe brain problems that has affected more than 21 million people in the world. To control this disease, there are two categories of drugs including old first generation drugs and new second generation drugs, with the latter drugs have less side effects and are more tolerated by the patient,” Hadizadeh said.
“Resperidone is a second-generation drug that is used for various diseases such as autism, hyperactivity, and bipolar disease,” he added.
“Autism is a disorder of unknown origin that both genetic and environmental factors play a role in its occurrence,” the researcher also said.
“Attention deficit hyperactivity disorder (ADHD) is also a neurological disorder with a well-known pattern of symptoms including inattention, hyperactivity, and irritability, leading to some degree of dysfunction,” he continued.
“Bipolar disorder is one of the most severe mental conditions among adolescents and children. This disorder includes psychosis, mania and extreme degrees of aggression and disorder. Risperidone is effective in improving the clinical symptoms of these diseases,” Hadizadeh added.
“Non-accompaniment of patients with psychotic disorders in treatment is one of the main problems in failed treatment. To reduce patient non-cooperation with oral administration, slow-release dosage formulations have been developed for several drugs controlling these disorders,” the researcher also said.
“One of the advantages of these pharmaceutical formulations is the reduction in acute symptoms compared to oral formulations. Also, the main advantage of the injectable slow-release system is that it maintains the drug in a therapeutic concentration for a long time. For example, one month, and there is no need to take the drug repeatedly orally,” he continued.
“This research helps to provide a new injectable formulation of risperidone, which can be welcomed by patients and pharmaceutical companies due to the ability to increase the release time and reduce its side effects,” he concluded.
4155/i
